Tuesday, July 22, 2025

 

Study finds “forever chemicals” in reusable feminine hygiene products



Indiana University and Notre Dame researchers uncover PFAS in nearly 30% of tested items, raising safety and transparency concerns



Indiana University





BLOOMINGTON, INDIANA — A new study from researchers at the Indiana University Paul H. O’Neill School of Public and Environmental Affairs and the University of Notre Dame shows that per- and polyfluoroalkyl chemicals (PFAS)—also known as “forever chemicals”—can be found in reusable feminine hygiene products. The pilot study provides information that will be useful for consumers, regulators, and manufacturers.

Published in Environmental Science & Technology Letters, the article, “Per- and polyfluoroalkyl substances in reusable feminine hygiene products,” presents findings from Indiana University Associate Professor Marta Venier and her Notre Dame colleagues, who tested 59 reusable personal hygiene products from North America, South America, and Europe across several product categories—period underwear, reusable pads, menstrual cups, and reusable incontinence underwear and pads. Researchers found the presence of PFAS at levels consistent with intentional use in nearly 30 percent of the samples, the first confirmation of PFAS in reusable feminine hygiene products.

“Since reusable products are on the rise due to their increased sustainability compared to single-use products, it’s important to ensure that these products are safe. This is crucial, especially for adolescents and young women, who are more vulnerable to potential negative health effects,” Venier said. “Feminine hygiene products stay in contact with the skin for extended periods of time, and the risks from the dermal absorption of PFAS, especially neutral PFAS, are not well understood.”

PFAS are linked to serious health risks. While further studies are needed to define the risk of PFAS exposure to human skin, the study’s finding that at least one sample per category showed no intentional presence of these chemicals suggests that safer and healthier alternatives can be manufactured without them.

“One of the most abundant PFAS detected in products from the North American market is 8:2 FTOH, a chemical that was voluntarily phased out in food packaging by manufacturers in accordance with the FDA due to persistence in the body after dietary exposure,” said Sydney Brady, a Ph.D. student in Venier's lab. “Notably, 8:2 FTOH can be transformed into more toxic PFOA once inside the body.”

The use of reusable feminine hygiene products is on the rise to combat the environmental impact of disposable products, yet they eventually end up in landfills. Once there, PFAS can leach into the environment, creating broader, indirect exposure.

The study’s findings highlight the importance of transparency from manufacturers and the need for consumers to have access to information about the materials used in the products they purchase.

“Consumers should know that not everything that is in a product is listed on the package,” Venier said. “Increased transparency from manufacturers would help consumers make informed decisions about what they’re purchasing for themselves and their families.”

 

Social steps to mitigate mental illness




PNAS Nexus



Mental illnesses are thought to be caused by both biological and environmental factors in complex interaction. Among the environmental contributors are a wide range of social, economic, and demographic factors known as “social determinants.” Adam Skinner and colleagues used dynamic Bayesian network analysis to infer the complex causal networks that link social determinants to mental health in a nationally representative sample, consisting of around 25,000 participants in the Household, Income and Labour Dynamics in Australia (HILDA) Survey. The authors identified variables that directly predicted mental health problems: physical health, loneliness, satisfaction with local community, and satisfaction with personal finances. In addition, the authors found that mental health problems influenced many of these same variables, suggesting feedback loops. According to the authors, these results can be used to identify the social and economic interventions that could most efficiently and effectively reduce mental illness at a population scale. For example, if every participant was satisfied with their financial situation, rates of mental illness would drop by around 3 percentage points, eliminating almost a third of mental illness in Australia. Significant public health gains could also be achieved by promoting local community engagement, physical wellbeing, and participation in volunteer or charity work and paid employment, perhaps through a nationally funded job guarantee program.

UN-AMERICAN

A new book, the structure of fair solutions, reshapes optimization by putting fairness first




Carnegie Mellon University





A new book, The Structure of Fair Solutions: Achieving Fairness in an Optimization Model, by Özgün Elçi, John Hooker, and Peter Zhang, challenges how people typically think about mathematical decision-making tools. Published by Springer Nature in 2025, the book argues that fairness should be a core principle in these models, not an afterthought.

Optimization models usually aim to maximize benefits or minimize costs, but this can unintentionally harm vulnerable groups. For example, a model designed to maximize life-years saved in organ transplants might overlook patients with rare conditions. Similarly, a traffic system focused on maximizing throughput could cause endless delays for some drivers. These are not flaws in the models themselves; they simply prioritize efficiency over fair outcomes.

The authors address the tension between efficiency and fairness directly. While designers often try to maximize things like profit or social welfare, truly incorporating fairness means moving beyond just efficiency-driven resultsThe book suggests that a solution balancing reasonable efficiency with clear fairness is always better than one that achieves peak efficiency but causes significant unfairness. Essentially, a truly optimal result is one that is fair.

Instead of suggesting that fairness be added to existing models, the book introduces a new way to evaluate fairness by looking at the actual structure of the solutions different models create. This means judging a model by its real-world effects, not just its theoretical assumptions. The authors examine various fairness models, including utilitarian, maximin, and bargaining-based approaches, and discuss how their solutions affect the incentives of different stakeholders and potential transfers. This approach helps readers make more informed and ethical choices, ensuring that the best solutions in our algorithm-driven world consider both efficiency and fairness.

 

Americans want stronger safety net for older adults





Cornell University





ITHACA, N.Y. — Social Security remains broadly popular, and as the U.S. population ages, more Americans think the government should do more to help families care for older adults, according to Cornell University-led research investigating shifting attitudes about aging policy.

Between 1984 and 2022, support for increased spending on Social Security grew to nearly 58%, up more than 8 percentage points, according to the researchers’ analysis of nationally representative surveys. The increase reflects a narrowing of the gap between Democrats and Republicans to a nearly negligible level.

Half of Americans now favor the government helping older adults to pay for everyday household tasks — such as grocery shopping, cleaning and laundry — up from roughly 38% since 2012, the analysis shows.

“There is strong support for Social Security, as well as the idea that the government should help provide or pay for care for older adults with care needs,” said Adriana Reyes, assistant professor in the Cornell Jeb E. Brooks School of Public Policy and lead author of the study. “There’s a pretty large consensus that we need to do more, and that’s an interesting and important shift in thinking.”

To explore how attitudes toward these issues have evolved over time and assess their policy implications, the researchers tapped the General Social Survey (GSS), a long-running, nationally representative survey.

In addition to consistent and growing support for securing Social Security, results showed growing support for government care programs over the decade since the GSS began posing questions about them. While roughly half of Americans want help paying for older adults’ household tasks, support for government provision of such services is weaker but growing, rising from 14% to 24%.

While support for Social Security is bipartisan, Democrats and independents are more likely than Republicans to back government payments for care.

For additional information, read this Cornell Chronicle story.

-30-

 

Investigational anti-cancer DNA therapy eases chronic osteoarthritis pain in dogs—pointing to a new non-opioid path for humans



Elenagen™, a DNA therapeutic previously shown to be safe and effective against lethal ovarian cancer, reduced chronic osteoarthritis pain with a 90% success rate in a peer-reviewed canine study





CureLab Oncology Inc.

Companion dog shows mobility improvement after Elenagen is administered 

video: 

Weekly p62 plasmid injections reduced limping and restored playful activity in dogs with severe osteoarthritis pain. After four doses, veterinary assessments, owner reports, and video documentation showed a marked reduction in limping and increased activity and playfulness. By six doses, most dogs exhibited near-complete improvement—limping ceased, and playful behavior returned. 

view more 

Credit: CureLab Oncology Inc.





BOSTONElenagen™, a novel DNA plasmid therapy that previously demonstrated high clinical benefit and low toxicity in cancer patients, has now shown significant promise in alleviating chronic pain demonstrating a 90% success rate. In a peer-reviewed study published in Frontiers in Veterinary Science (DOI: 10.3389/fvets.2025.1519881), Elenagen reduced osteoarthritis pain scores in companion dogs. Because the same pro-inflammatory cytokine loop drives osteoarthritis and other chronic pain states, the findings offer a promising translational signal for non opioid pain medicine. 

In the open‑label trial of 17 dogs aged 4–13 years, 90 percent achieved at least a one‑point drop in Pain Severity Score and a two‑point drop in Pain Interference Score after ten weekly intramuscular injections. Median Pain Severity fell from 5.25 to 3.25, and median Pain Interference from 7.00 to 3.27, by day 70. No treatment‑related adverse events were observed; hematology and serum chemistry remained within normal limits.

This outcome supports a mechanistic hypothesis: since chronic pain is known to result from both systemic inflammation and dysfunctional mesenchymal stem cells (MSCs)—and since Elenagen has been shown to reduce inflammation and restore MSC function—the therapy was expected to provide pain relief. The successful validation of this hypothesis may signal a potential, disease-modifying approach to treating chronic pain in both veterinary and human medicine. 

These dog data suggest we can help the body to manufacture its own multi‑modal anti‑inflammatory—without opioids or steroids,” said Dr. Alexander Shneider, founder and CEO of CureLab Oncology. “The majority of older cats and dogs suffer from osteoarthritis and the chronic pain it causes. Indeed, my four-legged family member, Sparky, is one of them. However, when I think of chronic pain, I see the faces of war veterans who survived the battlefield but did not survive the opioid addiction back home. While conducting this study, I’ve been thinking about them.

How an investigational p62 plasmid may ‘reset’ aging stem cells and break the inflammation–pain cycle

Chronic pain affects over 20% of adults worldwide and remains a major unmet medical challenge. Existing treatments, such as opioids, are often ineffective and carry serious risks. A growing body of research identifies chronic inflammation as a key underlying cause. In young, healthy individuals, mesenchymal stem cells (MSCs) help regulate inflammation and support tissue repair. But with age and disease, these cells undergo a harmful shift—losing their regenerative function and becoming active contributors to chronic inflammation and pain conditions, including those associated with arthritis.

CureLab Oncology developed Elenagen, a circular DNA (plasmid) encoding the p62 protein. In clinical testing with platinum resistant ovarian cancer patients, Elenagen significantly extended both time to disease progression and overall survival, also demonstrating a high safety profile. In collaboration with scientists at Camerino University (Italy), the CureLab team analyzed its anticancer mechanisms and demonstrated Elenagen’s broad systemic anti inflammatory effects and its ability to restore and modulate MSC function. Building on these findings, CureLab hypothesized that Elenagen could serve as an effective therapeutic for chronic pain by targeting its inflammatory root causes.

The core mechanism involves Elenagen reprogramming aged or dysfunctional MSCs. These cells, which shift toward a pro-inflammatory state and lose their regenerative capacity, are functionally ‘reset’ by Elenagen. Upon internalization of the plasmid, MSCs regain a youthful phenotype: they resume secreting anti-inflammatory factors and recover their ability to differentiate into functional cell types, such as osteoblasts (bone cells) rather than adipocytes (fat cells). Critically, the anti-inflammatory signals produced by Elenagen-reprogrammed MSCs travel over long distances and induce the same beneficial changes in remote MSCs as the plasmid itself—creating a system-wide amplification cascade.

Weekly p62 plasmid injections reduced limping and restored playful activity in dogs with severe osteoarthritis pain

Due to their size, natural development of chronic pain conditions such as osteoarthritis, and shared pathophysiological mechanisms with humans, dogs are considered one of the most clinically relevant translational models for studying chronic pain and testing novel therapies. In this study, dogs with severe osteoarthritis pain and limping received weekly intramuscular injections of Elenagen (1 mg). 

The results supported the hypothesis: after four doses, veterinary assessments, owner reports, and video documentation showed a marked reduction in limping and increased activity and playfulness. By six doses, most dogs exhibited near-complete improvement—limping ceased, and playful behavior returned. Video evidence can be viewed here

While joint structure remained unchanged, the observed functional improvement suggests that Elenagen targets pain biology directly, offering meaningful relief where structural therapies often fall short.

Significance and next steps

This pilot study provides important validation of Elenagen’s novel approach to treating chronic pain. Larger, placebo-controlled trials in both dogs and humans are planned for 2026. Elenagen’s well-established safety profile from prior human cancer trials significantly de-risks and accelerates its potential development pathway for pain management in both veterinary and human medicine.

Chronic pain caused by chemotherapy and other cancer treatments remains a major challenge in oncology, limiting both therapeutic options and patients’ quality of life. Elenagen’s potential to both delay disease progression and extend overall survival—while simultaneously reducing chronic pain—suggests a highly synergistic therapeutic profile. As a result, the company plans to incorporate chronic pain monitoring into its FDA and EMA cancer clinical trials starting in 2026.

About Elenagen
CureLab’s lead investigational compound is code-named Elenagen, an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In clinical studies conducted ex-US, Elenagen demonstrated desirable safety profile and statistically significant clinical benefit for cancer patients enhancing the anti-cancer effects of chemotherapy. Experimental results also demonstrate mitigation of chronic inflammation, anti-aging effects, and stimulation of an immune response to the tumor. 

About CureLab Oncology
CureLab Oncology Inc. is a pre-IPO, clinical-stage biotech company headquartered in the greater Boston area, Massachusetts. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelab.com.

 

Media contact:
Tim Cox, ZingPR, tim@zingpr.com